Benzinga | Apr 19, 2021 12:26PM EDT

Needham Maintains Buy on Haemonetics, Lowers Price Target to $108

Needham analyst Mike Matson maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $158 to $108.